Table 3.
Percentage and Adjusted ORs Predicting the Odds of Potential Poor-Quality Metrics by Facility Typea
| Variable | Community Cancer Program (n = 10,597) | Comprehensive Community Cancer Program (n = 71,271) | Integrated Network Program (n = 15,849) | Academic Cancer Program (n = 37,047) | NCI Program (n = 18,139) |
|---|---|---|---|---|---|
| Postoperative mortality | |||||
| 30 d | 3.6 | 2.7 | 2.3 | 2.2 | 1.4 |
| OR (95% CI) | 2.36 (2.00-2.78) | 1.78 (1.55-2.03) | 1.46 (1.23-1.72) | 1.61 (1.40-1.87) | 1 |
| 60 d | 5.2 | 4.0 | 3.4 | 3.2 | 2.0 |
| OR (95% CI) | 2.35 (2.05-2.69) | 1.76 (1.57-1.97) | 1.47 (1.28-1.69) | 1.60 (1.42-1.80) | 1 |
| 90 d | 6.3 | 4.9 | 4.1 | 4.0 | 2.6 |
| OR (95% CI) | 2.24 (1.98-2.53) | 1.70 (1.54-1.88) | 1.39 (1.23-1.57) | 1.54 (1.38-1.71) | 1 |
| 120 d | 7.2 | 5.8 | 4.9 | 4.6 | 3.0 |
| OR (95% CI) | 2.18 (1.95-2.45) | 1.71 (1.56-1.88) | 1.41 (1.26-1.58) | 1.53 (1.38-1.69) | 1 |
| Positive margin | 6.12 | 5.15 | 4.72 | 4.44 | 3.57 |
| OR (95% CI) | 1.65 (1.48-1.85) | 1.41 (1.29-1.54) | 1.26 (1.13-1.41) | 1.23 (1.12-1.35) | 1 |
| Wedge resection | 14.00 | 12.13 | 10.87 | 13.19 | 12.53 |
| OR (95% CI) | 1.19 (1.10-1.27) | 1.01 (0.96-1.06) | 0.93 (0.87-0.99) | 1.07 (1.01-1.13) | 1 |
| pNX rate | 7.29 | 5.18 | 3.65 | 4.45 | 2.67 |
| OR (95% CI) | 2.96 (2.63-3.33) | 2.10 (1.90-2.32) | 1.53 (1.35-1.74) | 1.69 (1.52-1.87) | 1 |
| < 10 lymph nodes resectedb | 73.26 | 67.56 | 61.29 | 59.62 | 47.68 |
| OR (95% CI) | 2.97 (2.80-3.15) | 2.28 (2.19-2.36) | 1.67 (1.59-1.75) | 1.60 (1.53-1.66) | 1 |
| Non-evidence-based use of adjuvant radiation therapyc | 4.45 | 2.91 | 2.65 | 2.58 | 1.77 |
| OR (95% CI) | 2.49 (2.13-2.92) | 1.70 (1.49-1.93) | 1.49 (1.27-1.75) | 1.42 (1.24-1.63) | 1 |
| Non-evidence-based use of adjuvant chemotherapyd | 9.80 | 8.33 | 8.21 | 7.64 | 6.99 |
| OR (95% CI) | 1.44 (1.30-1.61) | 1.30 (1.20-1.41) | 1.22 (1.10-1.34) | 1.08 (0.99-1.18) | 1 |
Data are presented as percentage unless otherwise indicated. NCI = National Cancer Institute. P < .0001 for all comparisons.
a
Adjusted for age at diagnosis, race or ethnicity, sex, year of diagnosis, insurance, geographic region of the facility, comorbidity score, and clinical stage.
b
Among patients with pathologic stage I-II, including patients with 0 lymph nodes, excluding patients with unknown number of nodes.
c
Defined as use in patients with pathologic N0 and N1 and negative resection margins.
d
Defined as use in patients with pathologic stage I with tumor size ≤ 4 cm and negative resection margins.